Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab

Cutis. 2020 Sep;106(3):131-132. doi: 10.12788/cutis.0066.

Abstract

Cutaneous T-cell lymphoma (CTCL) represents a diagnostic challenge because of its large symptomatic overlap with other common skin conditions such as atopic dermatitis (AD) and psoriasis. Dupilumab has offered promising results in AD treatment; however, concerns exist that its use may exacerbate undiagnosed CTCL. We present a patient with CTCL and concomitant AD who experienced improvement in both CTCL blood involvement and AD following the addition of dupilumab therapy.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Dermatitis, Atopic* / complications
  • Dermatitis, Atopic* / drug therapy
  • Humans
  • Lymphoma, T-Cell, Cutaneous* / complications
  • Lymphoma, T-Cell, Cutaneous* / diagnosis
  • Lymphoma, T-Cell, Cutaneous* / drug therapy
  • Skin Neoplasms* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • dupilumab